66 Participants NeededMy employer runs this trial

DISP-10 for Gastrointestinal Cancer

Recruiting at 1 trial location
DC
Overseen ByDispatch Clinical
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers.

The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.

Are You a Good Fit for This Trial?

Inclusion Criteria

My organs are working well enough for treatment.
I am 18 years old or older.
I have advanced or metastatic cancer of the esophagus, stomach, or colon.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose-Escalation

Evaluation of safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion

28 days

Dose-Expansion

Evaluation of safety and efficacy of DISP-10 in participants treated at the recommended dose for expansion

Up to 2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 15 years

What Are the Treatments Tested in This Trial?

Interventions

  • DISP-10

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: DISP-10Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dispatch Biotherapeutics

Lead Sponsor

Bristol-Myers Squibb

Industry Sponsor

Trials
2,731
Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia
Christopher Boerner profile image

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt profile image

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania